Compare Monolithic Power Systems Inc (MPWR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Repligen Corporation Common Stock — how do they compare? Monolithic Power Systems Inc trades at $1,227.32 (market cap $64.85B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Monolithic Power Systems Inc is far larger — about 5.8× Repligen Corporation Common Stock's market cap, and Monolithic Power Systems Inc pays a 0.61% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Repligen Corporation Common Stock for 0 Days on average.
| MPWR | RGEN | |
|---|---|---|
Market Cap | $64.85B | $11.14B |
Volume | 692,538 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $1.69K | $194.57 |
52-Week Low | $856.96 | $102.87 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $63.45B | $11.02B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,319.55 with minimal daily movement (+0.02%) amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, 24.5% net margins, and robust revenue growth from $2.8B to $3.3B year-over-year. Recent news highlights CEO share sales and a manufacturing partnership with GlobalFoundries to support AI and data center demand. Valuation remains elevated with P/E at 80.5 and P/S at 19.7, reflecting high growth expectations.
The outlook remains positive given analyst consensus (88% buy ratings) and a $1,830 price target, but risks include premium valuation compression, insider selling, and dependence on AI infrastructure growth. Cash flow strength supports dividend payments, though technical weakness near key support at $1,300 requires monitoring for sustained bullish momentum.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
